Needle-Free Transdermal Delivery Startup Prometheon Pharma Opens Platform to Promote Industry Partnerships

January 13, 2015 09:21 AM Eastern Standard Time

GAINESVILLE, Fla.--()--As the biotech industry and investors converge on San Franscisco for the JP Morgan Healthcare Conference, University of Florida spinoff Prometheon Pharma announced plans to open its needle-free transdermal patch technology platform to promote industry partnerships.

"We created a simple, de-risked, and success-based process that allows for quick decisions and minimal commitment. This allows partners to respond to changing markets or strategic plans," said Dr. Stephen Hsu, CEO of Prometheon Pharma and inventor of its technology.

The collaboration model is a simple fee-for-service contract designed to de-risk the development process for pharma/biotech partners and provide initial results in as few as 4 weeks. Prometheon will optimize its proprietaryTopicon™ ThermoMatrix™ formulations to deliver target molecules across a robust and validated human skin model to predict if its TruePatch™ product can achieve clinically meaningful bioavailability in patients.

This semi-high throughput model allows the testing of many drugs simultaneously to establish the dose-response range and saturating dose, and conduct tissue toxicology studies. These deliverables will be owned by the collaborator, who can then choose to progress to small animal studies through fee-for-service before pursuing a long-term partnership with Prometheon.

Setting a new industry standard, Prometheon created the first thermosensitive patches that maintain the stability of perishable large molecule drugs in a solid matrix at room temperature with its Topicon™ ThermoMatrix™ formulation. Upon application to the skin, the formulation melts into a dermoadhesive gel, which serves as a drug reservoir that delivers drugs at a constant and consistent rate.

Prometheon has already used its highly versatile platform technology in small animal models to deliver large peptide drugs such as insulin and human growth hormone, as well as a hair regrowth formula. ThermoMatrix™ patches could also deliver many other important small molecule and peptide drugs, as well as subunit vaccines and gene therapies.

About Prometheon Pharma LLC

Prometheon Pharma is a biotechnology company housed in the globally #1-ranked Sid Martin Biotech Incubator at the University of Florida. Prometheon is dedicated to increasing patient compliance and access as well as reducing healthcare costs with needle-free transdermal, low-refrigeration patches for large peptide and protein drugs.

Contacts

Prometheon Pharma
Devon Grimme, 386-418-0320
[email protected]
Website: http://www.prometheonpharma.com

 

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.